Since anti-human PDPN antibodies including NZ-1 also recognize normal cells such as lymphatic endothelial cells, a cancer-specific mAb (CasMab) that specifically recognizes human PDPN in tumor cells was established in 2014 [39]. The gene discussed is PDPN; the disease is cancer.